Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

A legfontosabb adatok

Ki végzi
Novartis Pharmaceuticals
Hol
Birmingham, Boston, Burlington, Columbus, Corvallis, Dallas, Evanston, Iowa City, Johns Creek, Murray, Pittsburgh, Rochester, San Francisco, Springfield, Stanford, The Bronx és Winston-Salem (Egyesült Államok)Mind a 18 helyszín megnézéseMég 17 másik országban, 80 helyszínen
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
316 fő vett részt
Kezdés
2024. jan. 18.
Befejezés
2026. máj. 14.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • TIN816 70 mg lyophilisate powder
  • Placebo
A regiszteradat frissítve
2026. július 29.

Ki vehet részt

Életkor
18 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 36 feltétel megnézéseKevesebb

Ki vehet részt

  • Signed informed consent must be obtained in accordance with local regulations
  • ≥ 18 to ≤ 85 years of age
  • Admitted to ICU or intermediate care unit/ high dependency care unit (HDU)
  • Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on:; Suspected or confirmed infection AND; Acute increase of SOFA score of 2 or more (excluding renal component). The baseline SOFA score should be assumed to be zero unless the participant is known to have pre-existing (acute or chronic) organ dysfunction before the onset of infection
  • Diagnosis of AKI Stage 1 or greater per the following criterion at randomization:; An absolute increase in serum or plasma creatinine by ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within 48 hours or presumed to have occurred in the previous 48 hours as compared to the reference serum creatinine
  • For participants with hospital-acquired AKI, a stable serum creatinine obtained in the hospital prior to AKI diagnosis should be used as the reference serum creatinine
  • For participants presenting from community, the reference serum creatinine should be estimated using the following order of preference:; The most recent value within 3 months of the hospital admission. If not available:; The most recent value between 3 and 12 months prior to hospital admission. If not available:; At hospital admission

Ki nem vehet részt

  • Receiving RRT or a decision has been made to initiate RRT within 24 hours after randomization
  • Sepsis diagnosis according to sepsis inclusion criteria for a period longer than 72 hours prior to ICU admission
  • Inability to administer study drug within 24 hours of diagnosis of AKI according to AKI inclusion criteria
  • Presence of AKI, in the Investigator's opinion, as suggested by clinical manifestation, e.g., prolonged oliguria or severe renal dysfunction on admission without a history of CKD, for a period longer than 24 hours prior to study drug administration
  • Evidence of recovery from AKI based on the investigator's clinical judgement prior to randomization
  • AKI is most likely attributable to other causes than sepsis, such as nephrotoxic drugs (Non-steroidal anti-inflammatory drugs (NSAIDs), contrast, aminoglycosides, etc.) or renal perfusion-related (acute abdominal aortic aneurysm, dissection, renal artery stenosis), urinary obstruction
  • Immunosuppressed patients; History of immunodeficiency diseases; Receiving immunosuppressant treatment or on chronic high doses (high-dose therapy exceeding 2 weeks of treatment) of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with corticosteroids (as per the Surviving Sepsis Guidelines) can be included
  • Patients with known or presumed latent or active TB based on clinical history or imaging e.g. patients on TB preventive therapy or close/household contacts of pulmonary TB patients
  • Active hematological malignancy (previous hematological malignancies that are not actively treated are allowable)
  • Use of other investigational drugs within 5 half-lives of enrollment, within 30 days (e.g., small molecules) or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations
  • Not expected to survive for 30 days due to medical conditions other than SA-AKI
  • Documented (biopsy proven) or suspected history of acute or sub-acute kidney diseases such as rapidly progressive glomerular nephritis (RPGN) and acute interstitial nephritis (AIN)
  • Known active hepatitis B or C infection (clinical diagnosis or positive infection serology), or advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C)
  • Acute pancreatitis with no established source of infection
  • Sepsis attributed to confirmed COVID-19
  • History of hypersensitivity to the study treatment or its excipients or to drugs of similar chemical classes
  • Any medical conditions that could significantly increase risk of participants' safety by participating in this study according to investigator's judgement
  • History of CKD with a documented estimated GFR <30 mL/min prior to admission to hospital
  • eGFR <45mL/min at admission without any other reference serum eGFR within last 12-months
  • Patients who are thrombocytopenic at screening (platelet count <50,000 per microliter) who have active/uncontrolled bleeding or who present current or past conditions indicating high risk for bleeding in the opinion of the investigator (e.g. coagulopathies, previous history of major non-traumatic bleeding etc.)
  • Not expected to survive for 24 hours
  • Weight is less than 40 kg or more than 125 kg
  • Limitations to the use of mechanical ventilation, RRT or vasopressors/inotropes (N.B. limitations on Cardiopulmonary resuscitation (CPR)e.g., do-not-resuscitate orders are not an exclusion criterion unless associated with likely poor outcome in next 24 hours)
  • AKI diagnosis according to AKI inclusion criteria over 48 hours after admission to ICU
  • Patients who are post-nephrectomy
  • Patients with permanent incapacitation
  • Burns requiring ICU treatment
  • Women with a positive pregnancy test, pregnancy or breast feeding
  • Women of childbearing potential, unless they are using highly effective methods of contraception for the entire duration of the trial

Helyszínek itt: Egyesült Államok

Még 17 másik országban, 80 helyszínen

  • University of AlabamaBirmingham, Egyesült Államok
  • Beth Israel Deaconess Med CenterBoston, Egyesült Államok
  • Massachusetts General HospitalBoston, Egyesült Államok
  • Lahey Hospital and Medical CenterBurlington, Egyesült Államok
  • Ohio State University Medical CenterColumbus, Egyesült Államok
  • Good Samaritan HospitalCorvallis, Egyesült Államok
  • Baylor Scott and WhiteDallas, Egyesült Államok
  • Northwestern Memorial HospitalEvanston, Egyesült Államok
  • Univ Of Iowa Hospitals And ClinicsIowa City, Egyesült Államok
  • Emory Johns Creek HospitalJohns Creek, Egyesült Államok
  • Utah Intermountain Medical CenterMurray, Egyesült Államok
  • U Of Pittsburgh Med CtrPittsburgh, Egyesült Államok
  • Mayo Clinic - RochesterRochester, Egyesült Államok
  • UC San Francisco Medical CenterSan Francisco, Egyesült Államok
  • Baystate Medical CenterSpringfield, Egyesült Államok
  • Stanford HealthcareStanford, Egyesült Államok
  • Montefiore Medical CenterThe Bronx, Egyesült Államok
  • Wake Forest Univ School of MedicineWinston-Salem, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).

A vizsgálat 4 csoportja

  • TIN816 Dose AA vizsgált kezelés

    Administered as a one time intravenous dose

    Kezelés: TIN816 70 mg lyophilisate powder

  • TIN816 Dose BA vizsgált kezelés

    Administered as a one time intravenous dose

    Kezelés: TIN816 70 mg lyophilisate powder

  • TIN816 Dose CA vizsgált kezelés

    Administered as a one time intravenous dose

    Kezelés: TIN816 70 mg lyophilisate powder

  • PlaceboPlacebo, összehasonlításként

    0.9% sterile saline administered as a one time intravenous dose

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
A regiszteradat frissítve
2026. július 29.